Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study.
Marconcini R, Fava P, Nuzzo A, Manacorda S, Ferrari M, De Rosa F, De Tursi M, Tanda ET, Consoli F, Minisini A, Pimpinelli N, Morgese F, Bersanelli M, Tucci M, Saponara M, Parisi A, Ocelli M, Bazzurri S, Massaro G, Morganti R, Ciardetti I, Stanganelli I.
Marconcini R, et al. Among authors: massaro g.
Front Oncol. 2022 Aug 15;12:917999. doi: 10.3389/fonc.2022.917999. eCollection 2022.
Front Oncol. 2022.
PMID: 36046043
Free PMC article.